Table 3.

Efficacy analysis in 82/85 preterm cases included in the caffeine citrate, intravenous, and enteral (CAFCIT) trial (3 cases are not included in the efficacy analysis because they had <6 apnea episodes/24 h at baseline) [58].

Study Characteristics	Caffeine	Placebo	p-value
number of cases evaluated	45	37
number (%) without apnea on day 2	12 (26.7%)	3 (8.1%)	0.03
apnea rate on day 2 (/24 h)	4.9	7.2	0.134
number (%) of cases with 50% reduction in apnea events from baseline to day 2	(76%)	(57%)	0.07